Quantcast
Channel: ABN Newswire
Viewing all 12704 articles
Browse latest View live

MMJ PhytoTech Ltd (ASX:MMJ) MediPharm Labs (CVE:LABS) Management Presentation

October 22, 2018, 6:07 pm
$
0
0
MMJ Group Holdings Limited (ASX:MMJ) (OTCMKTS:MMJJF) ("MMJ") is pleased to attach a copy of the management presentation published by MediPharm Labs Inc ("MediPharm Labs") (TSX-V: LABS).

The presentation is also available to view and download at:
ir.medipharmlabs.com/company-information

MMJ owns 5.88 million shares and 2.94 million warrants (exercisable at CAD$1.20 per share by October 2020) in MediPharm Labs.

To view the presentation, please visit:
http://abnnewswire.net/lnk/8VP95T0H 

Investor and Media Enquiries:
Jason Conroy
Chief Executive Officer
T: +61-2-8098-0819
E: info@mmjphytotech.com.au
↧
Search
↧

Ardea Resources Ltd (ASX:ARL) Presentation to the Australian Nickel Conference

October 22, 2018, 9:04 pm
$
0
0
Ardea Resources Ltd (ASX:ARL) (OTCMKTS:ARRRF) provides the Company's presentation to the Australian Nickel Conference.

Investment Summary

- Advanced Australian nickel and cobalt project at Goongarrie

o 141,912 m of RC drilling completed, plus diamond and sonic drilling for bulk metallurgy samples

o The Goongarrie Mineral Resource contains 1.5 million tonnes of nickel and 130,700 tonnes of cobalt

- Prefeasibility Study completed

o 1Mtpa and 1.5Mtpa case studies offer significant economic opportunity

o Scoping Study completed on 2.25Mtpa case shows excellent upside

- DFS Programs underway

- Positive metallurgical factors and test-work

- Leveraged to increasing nickel and cobalt demand from the rapidly growing EV and Static Storage Battery markets

To view the full presentation, please visit:
http://abnnewswire.net/lnk/33ML8U6G 

Ardea Resources Ltd
T: +61-8-6244-5136
E: ardea@ardearesources.com.au
WWW: www.ardearesources.com.au
↧

Queensland Bauxite Ltd (ASX:QBL) Annual Report to Shareholders

October 22, 2018, 9:17 pm
$
0
0
Queensland Bauxite Ltd (ASX:QBL) provides the Company's Annual Report to shareholders.

EXECUTIVE CHAIRPERSON'S LETTER

Dear Shareholders,

"This is just the beginning" - December 2017 Quarterly Report

What a significant year it has been for the company and our loyal shareholders. This letter begins by quoting the phrase I used in the QBL December 2017 Quarterly, 'This is just the beginning', and there is so much more yet to come!

I am very pleased to present, as QBL's Executive Chairperson and responsible for business development, on behalf of the Board of Queensland Bauxite Limited (ASX:QBL) (or "the Company"), our most significant Annual Report to date.

In October 2017 we began our International Expansion project by engaging the services of the Israeli Research Organisation, EndoCRO Ltd, to advise us on research and product development for GMP grade medical cannabis products. Our goal was to take Queensland Bauxite Ltd from purely an exploration company to a major dominant global player by making a strategic investment in Medical Cannabis Ltd (MCL) thus allowing us to enter the burgeoning multi-billion dollar medical cannabis industry whilst still pursuing our bauxite mining developments. To achieve this goal the Company has recently had to undertake a major transformation of its business activities from a mining and exploration entity, and through a recompliance we are creating the new parent company "Cann Global Limited" (ASX:CGB) which is scheduled to commence trading on the ASX in mid-November, with the approval of the ASX. Our newly branded Cann Global Limited will oversee our medical cannabis, hemp food and mining divisions.

We are pleased to report that during the past 12 months QBL has successfully entered into formal agreements, joint ventures and is presently undertaking projects with no fewer than 11 Australian and International companies such as:

EndoCRO Ltd, Israel, for the formulation of a unique medical Cannabis drug delivery system;

CannTab Therapeuritics Ltd, Canada, for the rights to exclusively manufacture and distribute throughout Australia and Asia their exclusive pharmaceutical grade GMP (XR) CannTab pills intended to assist in alleviating some symptoms of various chronic illnesses and to assist with pain management;

Affinity Energy Health Limited (formerly Algae.Tec), is licensing our unique Cannabis cultivar seed bank to formulate Cannabis medicinal products for veterinary medications;

Certara, USA, is providing pharmaceutical consultative services for the development and distribution of the CannTab XR medication here in Australia. Drs Andreas Wallnoefer and Graham Scott are providing technical oversight;

THE TECHNION, Israel. MCRG, our Medical Cannabis Research group, has signed an agreement to fund the research studies of Dr David (Dedi) Meiri Ph.D., and his team as they investigate the intervention of medicinal cannabis to disrupt the debilitating mechanisms of Autoimmune Disease, in particular, Multiple Sclerosis. MCRG has the rights to an exclusive license agreement to benefit from any discoveries that come as a direct result of the research being conducted by Dr Meiri and his team. The team has already had ground breaking success in the lab in the first 6 months of this research with human trials currently being progressed;

John Easterling, Amazon Herb Co., a world-renowned expert in Cannabis Therapeuticals, and influential advocate for the medical cannabis industry, has joined the team of Medical Cannabis Ltd. John is providing valuable consultative services to all our MCL Projects;

Hemp Hulling Co, Queensland, oversees the processing and packaging of all our Hemp Seed nutritional products and Hemp Seed oil. We are very pleased to have the professional services of the Edwards family who are managing and developing this division;

VitaHemp's Seed and processing Division, HHC, and partners Waltanna Hemp Group, providing our Hemp Seed ingredients for the 'Red Tractor' group which currently supplies these products in hundreds of Coles stores around Australia;

T12 Holdings Ltd, managed by Seb and Sam Edwards, will be the main support company for our Retail brands: VitaHemp, Organic Markets Direct (OMD), EM Superfoods, Australian Grown Naturals, Blanck & Co., and Black Bag. These brands providing Certified Organic Foods such as hemp Food, Chia, Green Leaf Stevia, Brown Rice, Quinoa, BuckWheat and Cacao;

Medcan Australia will be overseeing our research, cultivation , production and manufacture of medical cannabis GMP pharmaceutical grade formulations, therapeutics, and nutraceuticals. The team is being led by Craig Cochran and Gareth Ball;

PharmoCann Israel, for the rights under a 50/50 JV agreement, to exclusively cultivate, manufacture and distribute throughout Australia and internationally Pharmocann's exclusive medical cannabis products together with their unique cultivation, manufacturing and product IP and expertise developed over many years.

The Board is also pleased that the South Johnstone Bauxite Project continues to progress towards achieving milestones and completing tests required to secure its final ML. Our Project team has met with the management and boards of international bauxite and alumina processing companies in China who have shown an interest to discuss partnering in the development of this project and discussions are continuing as we work towards finalising offtake partnerships.

At the recent E.G.M. we were very pleased to have received overwhelming support for the approval of the 14 resolutions to take our company to the next stage in its development. In particular, and on behalf of the Board, I would like to thank all of our shareholders who participated in our recent successful capital raise (CR). Allocations will be confirmed in the coming weeks taking into account priority to longer term shareholders, larger shareholders, and those who applied earlier.

It is our belief that the following 12 months will be a significant year in the development and life of our company as we: 1) Bring on line our new medical cannabis facilities in Queensland for the cultivation and manufacture of the Canntab and Pharmocann medical cannabis products and formulations, 2) Increase our penetration into the natural health food sector in Australia and globally with our new range of organic and health foods, 3) Increase our footprint, yield and acreage on our hemp farms in NSW, Victoria and Tasmania, and 4) progress our research work to develop unique medical products, particularly the cutting edge research being undertaken on our behalf by Dr Meiri and his team at the leading Cannabis research lab located at the Technion in Haifa Israel.

We look forward to profitable returns on our investments and increasing shareholder wealth moving forward into 2019.

My thanks go to the Board, the entire management team, and to our shareholders for their invaluable support and contribution towards the fast progressing success of our company.

To view the Annual Report, please visit:
http://abnnewswire.net/lnk/UP20PMI3 

Queensland Bauxite Ltd
Tel: +61-2-9291-9000

For further information or any queries please email the Company at:
sfeldman@queenslandbauxite.com.au
↧

Anatara Lifesciences Ltd (ASX:ANR) Formation of Product Development Advisory Board

October 22, 2018, 9:39 pm
$
0
0
Anatara Lifesciences (ASX:ANR), a company focused on commercialising innovative products for gut health, is pleased to announce the formation of its Product Development Advisory Board. The Advisory Board consists of five key external experts: Dr Rebecca Burgell, Dr Jakob Begun, Prof Barry Campbell, Assoc Prof Simon Keely and Prof Peter Gibson, who will serve as the Chairman.

Key points:

- New Product Development Advisory Board includes prominent scientists:

o Prof Peter Gibson, Director of Gastroenterology, The Alfred and Monash University, Melbourne, VIC, who will serve as Chairman

o Dr Rebecca Burgell, Consultant Gastroenterologist, The Alfred and Monash University Melbourne, VIC

o Dr Jakob Begun, Clinical Lead, Mater Hospital and IBD Group Leader, Mater Research Institute, University of Queensland, Brisbane, QLD

o Prof Barry Campbell, Gastroenterology Research Unit, Department of Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, UK

o Assoc Prof Simon Keely, Chief Investigator, Hunter Medical Research Institute (HMRI) Gastrointestinal Research Group, Newcastle, NSW

- The Product Development Advisory Board will guide Anatara's scientific programs and product development strategies

The newly appointed Advisory Board will work closely with the Anatara Board and management team as it continues to advance its human gastrointestinal (GI) health program, in the burgeoning gut health market. The Advisory Board will provide advice on issues relating to Anatara's research priorities and strategies, and the Company's product development programs.

Sue MacLeman, Non-Executive Chair, Board of Directors said, "We feel privileged to have attracted advisors with world-leading experience in gastrointestinal disorders to join Anatara's inaugural Advisory Board. The group will assist with guiding our scientific programs and will advise on our long-term strategic goals. Their expertise will be valuable as we look toward commercialising our first human product candidate, the Gastrointestinal Reprogramming (GaRP) dietary supplement, and to the further development of our human product pipeline."

Professor Peter Gibson will assume the role of Chairman and has more than 30 years' experience in gastrointestinal health. He is recognised globally as an expert physician and researcher and was awarded the Distinguished Research Prize by the Gastroenterological Society of Australia in 2010.

"Anatara's focus on human gastrointestinal disorders is an exciting new development in the growing gut health space. Irritable Bowel Syndrome (IBS) is a chronic condition that affects up to 15% of all Australians at some point in their life," said Professor Peter Gibson. "Together with my Advisory Board colleagues, I look forward to assisting Anatara as they develop products to assist with the debilitating symptoms associated with gastrointestinal disorders such as IBS."

Dr Tracie Ramsdale, Interim CEO and Non-Executive Director, commented, "It is a testament to the potential of Anatara's human gastrointestinal health program that we have been able to attract such prominent scientists and clinicians to our product development Advisory Board. We continue to focus on the development of our GaRP dietary supplement program, which we hope will serve to greatly assist patient wellbeing for those with gastrointestinal disorders like Inflammatory Bowel Disease and Irritable Bowel Syndrome."

She continued, "GaRP is being developed to be a multi-component dietary supplement, designed to address the primary underlying factors associated with gastrointestinal disorders, such as inflammation, a dysfunctional microbiome, impaired intestinal barrier function and mucosal damage. The advisory board will meet twice yearly, as well as when needed for specific additional purposes, as we accelerate GaRP's proof of concept studies and assess other potential product opportunities in gastrointestinal health."

Full biographies for each member of the Anatara Lifesciences Advisory Board are available below.

Professor Peter Gibson

Professor Peter Gibson is the Director of Gastroenterology at The Alfred and Monash University, having previously been Professor of Medicine at Eastern Health and Head of the Eastern Health Clinical School. He is a Past-President of the Gastroenterological Society of Australia. From a background of research in epithelial cell biology, he now directs a large program of translational research, and has active clinical interests in inflammatory bowel disease, coeliac disease and irritable bowel syndrome. A major focus of his work is the use of diet to control gut symptoms and influence outcomes in chronic intestinal conditions such as irritable bowel syndrome and inflammatory bowel disease. He has published widely on these topics. He was awarded the Distinguished Research Prize by the Gastroenterological Society of Australia in 2010.

Doctor Rebecca Burgell

Dr Rebecca Burgell is a consultant gastroenterologist with an interest in inflammatory bowel disease, clinical nutrition, pelvic floor dysfunction and functional gastrointestinal disorders. She is the Head of the Functional Gastrointestinal disorders service and medical lead of the home enteral nutrition program at Alfred Health. Dr Burgell has a PhD from the University of London examining the physiology of the lower bowel in patients with severe functional constipation at the National centre for bowel research and surgical innovation based at Bart's Health in London. She is expert in performing anorectal physiology investigations and endoanal ultrasound and is a member of the International Anorectal Physiology Working Group. Dr Burgell currently works fulltime at Alfred Health and Monash University.

Doctor Jakob Begun

Dr Jakob Begun obtained his MD and PhD in genetics at Harvard Medical School. His advanced training in Gastroenterology and Inflammatory Bowel Disease (IBD) was at Massachusetts General Hospital (MGH) where he developed a keen interest in the microbiome - immune system interactions. He returned to Australia in 2014 to pursue his interest in clinical IBD and research. He is the IBD clinical lead at the Mater Hospital Brisbane and IBD Group leader at the Mater Research Institute - University of Queensland. He runs a basic and translational laboratory investigating the interaction between innate immune functions of the gut and the microbial community. He also performs clinical research examining the natural history of IBD, endoscopic assessment and intervention, and identifying barriers of care for adolescents and young adults with IBD at the Mater Young Adult Health Centre. He serves on the steering committees of the Australia and New Zealand IBD Consortium and the Australian IBD Association.

Professor Barry Campbell

Professor Barry Campbell is a holds a professorship in University of Liverpool's Institute of Translational Medicine. Barry started his scientific career in gut endocrine physiology at UCNW Bangor, receiving a BSc with Honours in Zoology in 1988, and a PhD in Physiology from University of Liverpool in 1991. Following an MRC-funded post-doctoral research position, he held a Wellcome Trust-funded lectureship in intestinal physiology, before being appointed to a full-time academic post in Medicine at Liverpool where his research led to specific understanding of the causes and consequences of altered intestinal mucosal glycosylation that occurs in intestinal inflammation and cancer.

Professor Campbell now leads one of the key international translational research groups investigating bacteria-host intestinal epithelium interactions, particularly focused on Crohn's disease- and colorectal cancer-mucosa associated Escherichia coli. This includes laboratory studies on epithelial and immune cell responses in 2D cell-line and 3D organoid cultures, and in ex vivo tissue, and translational medicine projects examining effects of antibiotics, environment modulating agents and dietary components. He was awarded a Personal Chair within the University of Liverpool's Institute of Translational Medicine in 2013. He is a member of the UK Gut Microbiota for Health Expert Panel and the 'Scientists in Gastroenterology' lead for the British Society of Gastroenterology, supporting education, research and the annual meeting Translational Science Masterclass symposia.

Associate Professor Simon Keely

Dr Keely is chief investigator of the Hunter Medical Research Institute (HMRI) Gastrointestinal Research Group. Dr Keely graduated with a Ph.D. from University College Dublin. He undertook postdoctoral research training at the Mucosal Inflammation Program in University of Colorado Denver, receiving a prestigious fellowship from the Crohn's and Colitis Foundation of America. His research group at the HMRI is a multidisciplinary team of biomedical and clinician researchers investigating the molecular mechanisms of gastrointestinal diseases such as inflammatory bowel disease, colorectal cancer and functional GI disorders. Dr Keely is particularly interested in understanding changes in both tissue metabolism and host-microbe interactions during mucosal inflammation and how these changes relate to GI immunopathology and loss of immune homeostasis. The ultimate goal of this research is to understand how these factors can be manipulated for therapeutic benefit. Dr Keely has specialist expertise in in vitro, ex vivo and in vivo models of IBD and IBS. His work been published in leading gastroenterology and basic laboratory science journals and he is a consultant for a number of pharmaceutical companies. 

Investor inquiries
Sue MacLeman
Chair
Anatara Lifesciences
T: +61-437-211-200
E: smacleman@anatara.com

Media inquiries:
Jane Lowe
IR Department
T: +61-411-117-774
E: jane.lowe@irdepartment.com.au
↧

FINANCE VIDEO: Geopacific Resources Ltd (ASX:GPR) DFS Update

October 22, 2018, 9:40 pm
$
0
0
Geopacific Resources (ASX:GPR) (OTCMKTS:GPACF) has provided an updated on the progress of the Definitive Feasibility Study for their Woodlark gold project in Papua New Guinea. We discussed with the company the progress of the study, potential cost savings as well as the progress of project financing options.

To view the video, please visit:
http://www.abnnewswire.net/press/en/95096/GPR 

Adam Kiley
Director
TSI Capital Pty Ltd
E: adam.kiley@tsicapital.com.au
↧
↧

Cryptocurrency Exchange Binance.com (CRYPTO:BNB) Will List Decred (CRYPTO:DCR) on 2018/10/24

October 22, 2018, 10:55 pm
$
0
0
Cryptocurrency Exchange Binance.com (CRYPTO:BNB) will open trading for DCR/BNB (CRYPTO:DCR) and DCR/BTC trading pairs at 2018/10/24 04:00 AM (UTC). Users can now start depositing DCR in preparation for trading.

Decred Listing Fee: 0 BNB

Details:

Decred is similar to normal money. It's a currency. The big difference: Decred is designed to be completely autonomous, open source, and driven by the community. No central banks needed.

Decred is similar to Bitcoin. There will only be 21M coins created, ever. The big difference: Decred uses advanced and innovative technology that solves blockchain governance. No hard forks needed. Exchanges will never have to deal with customer requests for splits. The general public will never have to sift through contentious forks or be fooled by claims of a "better Decred".

The Decred project was created in the spirit of open participation. Everyone can join and contribute. All stakeholders of Decred can decide to take part in the decision-making process. The project is constantly evolving, so you can expect more in the future.

Max Supply: 21,000,000

Circulating Supply: 8,687,121 

Binance
E: market@binance.com
WWW: www.binance.com

Decred
WWW: www.decred.org
↧

Alt Resources Ltd (ASX:ARS) Corporate Presentation

October 22, 2018, 11:08 pm
$
0
0
Alt Resources Ltd (ASX:ARS) provides the Company's latest Corporate Presentation.

Why Invest?

- Large and strategic landholding in the prolific Mt Ida gold belt;

- Several positive pricing catalysts in the near term;

- Attractive valuation relative to peers;

- Strong news flow from rapid development strategy;

- Experienced management team with track record of generating shareholder returns.

An opportunity to share in our exciting future...

To view the full presentation, please visit:
http://abnnewswire.net/lnk/27L140PQ 

James Anderson
CEO Alt Resources Ltd
M: +61-406-069-243
E: james.anderson@altresources.com.au

Andrew Sparke
Director
E: andrew@olivecapital.com.au
M: +61-422-283-022
↧

Regeneus Ltd (ASX:RGS) Quarterly Results for the Period Ended 30 September 2018

October 23, 2018, 4:08 pm
$
0
0
Regeneus Ltd (ASX:RGS) provides the Company's quarterly results for the period ended 30 September 2018.

The financial highlights for the quarterly reporting period include:

- Cash as at 30 September 2018 of $2.7 million (30 June $1.1 million)

- Net operating cash outflow (ex R&D Tax Incentive) of $1.5 million, consistent with prior quarters

- R&D Tax Incentive received of $2.4 million (2017 $2.6 million)

- Repayment of R&D loan facility with Paddington St Finance Pty Ltd renegotiated to the earlier of receipt of the next milestone payment under the manufacturing licence with AGC Inc.; the receipt of the FY19 R&D Tax Incentive; and 30 September 2019.

The Company's cash position of $2.7 million as at 30 September is expected to provide adequate funding until the next milestone payment is received under the Company's Progenza licence agreement with AGC Inc. of Japan.

The sources of funding for the Company over the next 18 months include: milestone payments and anticipated clinical licensing opportunities for Progenza; shareholder loan repayments relating to the funding of employee options exercised as part of the IPO in 2013; ongoing R&D Tax Incentives including forward funding arrangements where necessary and options exercised. These sources of cash are expected to provide sufficient funding to support the Company's R&D, clinical trials and operating activities for FY'19 and into FY'20.

Further licensing opportunities may provide additional funding for incremental activities. 

Sandra McIntosh
Company Secretary and Investor Relations
Regeneus Ltd
T: +61-2-9499-8010
E: investors@regeneus.com.au

Media
Imogen Conyers
Media and Capital Partners
T: +61-405-191-257
E: imogen.conyers@mcpartners.com.au
↧
Search

Queensland Bauxite Ltd (ASX:QBL) Strategic Collaboration and Supply Agreement Signed with Canadian Licensed Producer

October 23, 2018, 4:24 pm
$
0
0
The Board of Queensland Bauxite Limited (ASX:QBL) (or 'the Company') is very pleased to announce a materially strategic transaction, that its soon to be wholly owned subsidiary Medcan Australia, has entered into a Strategic Collaboration and Supply Agreement Signed with an established Canadian Licensed Producer of Medical Cannabis.

As a result of a relationship forged over the past two years, Medcan Australia (Medcan) has formalised a significant Collaboration Agreement with Bonify Holdings Corporation (Bonify), a Canadian Licensed Producer of Medical Cannabis, for Medcan to provide medical cannabis products to Bonify for distribution in the bourgeoning Canadian market.

Highlights of the Strategic Collaboration Agreement

- Under the Strategic Collaboration Agreement (SCA), Bonify has agreed to arrange for the delivery to Medcan of cannabis plant (Material) that is to be used by Medcan to manufacture the Material into bulk dried cannabis flowers.

- Importantly, Medcan will be provided with Bonify's genetics by way of seed stock/tissue culture and it will immediately obtain from Bonify an amount of finished end user packaged products to cater for Medcan's Australian patients.

- The intent of the SCA is for the parties to build a mutually beneficial and profitable relationship, and for that purpose they agree to continue dialogue around further collaboration opportunities relating to (but not limited to) genetics, product development and supply.

Further Information in respect of the Strategic Collaboration Agreement

The SCA includes general terms relating to placing of orders, the performance of the manufacturing services, regulatory compliance in respect of the manufacturing which will be undertaken by Medcan, end product deliverables, and the like.

Medcan shall, at its own expense, obtain and maintain the necessary permits, registrations, licenses, or other regulatory approvals required for the manufacture of the end product. Bonify shall at its own expense, obtain and maintain any permits, registrations, licenses, or other regulatory approvals in respect of the material and the end product, or the import, export, marketing, sale, distribution or use of the end product in or into any jurisdiction in which it markets, sells or distributes the end product.

The term of the SCA is a period of 1 year, in which it is intended for Medcan to initially supply Bonify with 3000kgs of dried flower, and it renews automatically year on year for successive 1-year periods, unless written notice of the intention not to renew is given by either side within 60 days before the renewal term expires.

It is anticipated that this supply will commence approximately 14-16 weeks from receipt of Medcan's receipt of the first Materials supplied by Bonify and will continue with shipments on a quarterly basis for the initial term of the agreement. It is anticipated that the Medcan facility will be fit out and operational by early 2019.

The parties have acknowledged that whilst Medcan and Bonify will use best efforts to adhere to the timeframes specified within the agreement, the timeframes may be subject to variation in order to comply with relevant Australian and Canadian legislative requirements. Whilst the agreement is expected to be significant for the Medcan business, it is not possible to definitively quantify expected revenue at this stage.

The agreement may be terminated immediately by giving written notice if either party fails to remedy a material breach of the provisions of the agreement within 30 days of being notified by the other party in writing of the relevant breach.

Either party may also terminate the agreement immediately by giving written notice if the other party is declared insolvent or bankrupt, or a voluntary petition of bankruptcy is filed in any court of competent jurisdiction by a third party; or the other party ceases or threatens to cease to carry on business; or the agreement is assigned by the other party for the benefit of creditors.

Medcan may terminate the agreement in the event Bonify does not deliver the Materials. Bonify may (acting reasonably) terminate the agreement by giving 30 days written notice in the event Medcan fails to manufacture the Material into End Product within the timeframes specified in the agreement.

Each party provides representations and warranties as to their legal status and corporate authority, and in respect of the Materials or End Product to be delivered which are standard for an agreement of this nature. Medcan and Bonify also provide mutual indemnities in respect of, among other things, any loss suffered (excluding consequential loss) as a result of a breach of the SCA, except to the extent such losses are attributable to the negligence or wilful misconduct of the relevant indemnified party.

Medcan Australia's CEO, Craig Cochran says, "We are delighted to announce this strategic agreement with Bonify. This agreement is the culmination of over 24 months of discussions and hard work between our companies. We consider this a huge step forward for the International Medicinal Cannabis industry and more specifically Australian export of Medicinal Cannabis products. It aligns with Australian Health Minister Greg Hunt's announcement in February 2018 that Australia "aims to be the world's number one exporter of Medicinal Cannabis". This agreement also opens the door for numerous other opportunities between our companies around research and product development."

Medcan Australia's BDM, Gareth Ball adds, "With patient access still being a huge issue in Australia, an international agreement of magnitude provides a platform for an industry push around Australian patient access. Medcan's vision has, and always will be, to provide the highest level of Medicinal Cannabis products to Australian patients. Agreements like this allow Australian Medicinal Cannabis companies the ability to operate with a level of profitability as the push for better patient access in Australia continues."

Bonify's President and Chief Executive Officer, Dalbir Bains, comments: "We are excited to be working together with Medcan to help us ensure our Canadian customers are provided with the products they both want and need. This Agreement allows us to further increase our Canadian market offering, while it simultaneously opens the door for bilateral supply agreements and further international product development and research collaborations between our two companies.

About Bonify

Bonify is a Canadian-owned leading provider of quality Cannabis. By maximizing research findings and strictly adhering to best in class practices, quality standards and procedures, Bonify produces Cannabis solutions to help individuals get the most out of life each and every day.

To learn more, please visit http://www.bonify.com

Contact Information

Please call 1.844.586.3556 or contact communications@bonify.com with any media related questions or requests. 

Queensland Bauxite Ltd
Tel: +61-2-9291-9000

For further information or any queries please email the Company at:
sfeldman@queenslandbauxite.com.au
↧
↧

Intermin Resources Limited (ASX:IRC) Quarterly Activities Report 30 September 2018

October 23, 2018, 4:41 pm
$
0
0
Intermin Resources Limited (ASX:IRC) ("Intermin" or the "Company") is pleased to provide the September 2018 Quarterly Activities Report. Intermin is a gold exploration and development company with a key focus in the Kalgoorlie region of Western Australia (see Figure 1 in link below) and has a number of joint ventures in place with quality partners covering multiple commodities in Western Australia and Queensland.

HIGHLIGHTS

- Fully funded 55,000m Resource extension and new discovery drilling program continues with 20,336m drilled at the Anthill, Binduli and Blister Dam projects during the Quarter

- Highly successful new discovery and resource expansion drilling campaign completed at the Teal gold project area, 11km north-west of Kalgoorlie-Boulder

- Updated independent Mineral Resource estimate released for the Teal Project area and, after depletion from mining Teal Stages 1 and 2, stands at:

o 4.25Mt @ 2.11g/t Au for 289,000 ounces at a 1.0g/t Au lower grade cut-off, up 80%(see Note 1 below)

- Over 85% now in the Indicated Category with mineralisation open in all directions (see Note 1 below)

- Intermin's Total Mineral Resource (after depletion) grew to:

o 8.40Mt @ 2.08g/t Au for 562,000oz at a 1.0g/t Au lower grade cut-off (see Note 1 below)

- Excellent first pass drilling results received from the Crake prospect with follow up drilling now underway and results expected in the December Quarter (see Note 2,5 below)

- Initial drilling results received from the Anthill gold project with further results and an updated Mineral Resource estimate expected in the December Quarter (see Note 3,5 below)

- A total of 3,946,347 IRCOA options exercised during the Quarter raising A$670,879 and 4,250,000 unlisted Director options exercised raising A$406,250

- Cash and tradeable securities of A$8.65 million (see Note 4 below)

- Infill and regional exploration drilling to commence at the Richmond vanadium project in the current Quarter with results expected in the March Quarter 2019 (see Note 5 below)

- Metallurgical testwork continues on ore samples from the vanadium project with further pre-concentration and downstream processing tests on going

- Drilling commenced at the Blister Dam gold project on the Zuleika Shear with results expected in the December and March quarters (see Note 5 below)

- Janet Ivy Mining Royalty payments of A$0.50/t continue with A$196,000 received for the June Quarter and regular quarterly payments expected through CY2018 (see Note 5 below)

DECEMBER QUARTER ACTIVITES (see Note 5 below)

- Resolution of purported variation claims received from mining contractor Resource Mining Pty Ltd over the Teal open cut gold mine

- Ongoing resource expansion and new discovery drilling at Binduli and Blister Dam

- Further drilling results from the Anthill, Binduli and Blister Dam gold projects

- Richmond Vanadium metallurgical test work results on ore pre-concentration optimisation

- Resource update for the Anthill project

- Stakeholder engagement and drilling at the Richmond vanadium prospect

Notes:

1 As announced to the ASX on 19 September 2018,

2 As announced to the ASX on 10 July and 15 August 2018,

3 as announced to the ASX on 21 August 2018,

4 Includes 75% profit share component from Teal gold mine as per Intermin's position, see Page 4 for details,

5 see Forward Looking and Cautionary Statement on Pages 29 and 30

To view the full report, please visit:
http://abnnewswire.net/lnk/A1JNMW77 

Jon Price 
Managing Director
Tel: +61-8-9386-9534
E: jon.price@intermin.com.au

Michael Vaughan
Media Relations - Fivemark Partners
Tel: +61-422-602-720
E: michael.vaughan@fivemark.com.au
↧

Core Exploration Ltd (ASX:CXO) Benchmark Cathodes Presentation

October 23, 2018, 4:45 pm
$
0
0
Core Exploration Ltd (ASX:CXO) provides the Company's Benchmark Cathodes Presentation.

Huge exploration upside

Targeting substantial Mineral Resource growth

Upcoming exploration and aggressive drill programs in 2018 to target growth in the resource base to support a long-life lithium production hub at Finniss Project

Discoverers - Core's exploration has discovered some of the highest grade lithium in Australia, capable of producing a quality spodumene concentrate

Numerous high grade lithium pegmatite targets already identified

High potential for additional resources from 500km2 covering 100s of pegmatites

Three rigs currently drilling at Finniss with 40,000m of drilling to be conducted over 12 months

Drilling results over coming weeks and months leading to multiple Resource increases and upgrades

To view the full presentation, please visit:
http://abnnewswire.net/lnk/EF6IK3R0 

For further information please contact: 

Stephen Biggins
Managing Director
Core Exploration Ltd
T: +61-8-8317-1700

For Media and Broker queries: 

Warrick Hazeldine
M: +61-417-944-616

Andrew Rowell
M: +61-400-466-226
Cannings Purple
↧

New Energy Minerals Ltd (ASX:NXE) Investor Presentation October 2018

October 23, 2018, 7:55 pm
$
0
0
New Energy Minerals Ltd (ASX:NXE) (FRA:GGY) provides the Company's latest Investor Presentation.

BUILDING STRONGER, SAFER BUILDINGS

- Graphite is a key material in the expandable graphite market, which is widely used in the next generation of fire-retardant material building materials.

- With China forecasted to require a total of 40Mtpa of fire-retardant building materials per year, and 5% of this product being made of Graphite, this equates to 2 million tonnes of high quality large-flake graphite per year being consumed by the Chinese construction industry alone.

- To add context, it is estimated total global production of flake graphite in 2016 was approximately 860,000 tons with only a proportion of this material used to generate expandable graphite.

- It is commonly understood that China's coarse flake graphite reserves have largely diminished, and supply is also under threat by environmental restrictions forcing mine closures.

- The Caula project has significant capacity to supply this market and exceptional flake size distribution with >63% of concentrates larger than 180 microns @ 97% to 98% TGCC. New Energy Minerals has initiated further testing on its 180+ concentrates to assist with offtake discussions.

To view the full presentation, please visit:
http://abnnewswire.net/lnk/E6YP3K7Q 

New Energy Minerals Limited
Bernard Olivier
Managing Director
E: bernard@newenergyminerals.com.au
M: +61-4-08948-182
T: +27-66-4702-979

Jane Morgan Management
Jane Morgan
Media & Investor Relations
E: jm@janemorganmanagement.com.au
T: +61-405-555-618
↧

MMJ PhytoTech Ltd (ASX:MMJ) Harvest One (CVE:HVT) Senior Management Appointment

October 23, 2018, 9:03 pm
$
0
0
MMJ Group Holdings Limited (ASX:MMJ) (OTCMKTS:MMJJF) (MMJ) is pleased to note the attached release by Harvest One Cannabis Inc (CVE:HVT) ("Harvest One") confirming the appointment of Will Stewart as its Senior Vice President, Corporate and Public Affairs. MMJ is the largest single shareholder in Harvest One.

To view the release, please visit:
http://abnnewswire.net/lnk/USO4110F 

Investor and Media Enquiries:
Jason Conroy
Chief Executive Officer
T: +61-2-8098-0819
E: info@mmjphytotech.com.au
↧
↧

FINANCE VIDEO: BeefLedger Ltd (SOAR:BEEF) Interview with Charles Morris

October 23, 2018, 9:04 pm
$
0
0
BeefLedger Ltd (SOAR:BEEF) Director Charles Morris is interviewed by Tim Mckinnon of ABN Newswire regarding tackling food fraud with blockchain technology.

Beefledger is driven by a belief that consumers and all supply chain participants can benefit from greater transparency and streamlined transactions in the beef supply chain.

Food safety and fraud concerns are massive issues, especially in places like China. Australia is a premium producer of safe, high quality food products - including beef - which is increasingly sought out by Chinese consumers. BeefLedger is developing and commercialising an integrated blockchain-enabled beef provenance platform and smart contracting payments regime that streamlines payments and strengthens consumer confidence in product credentialing.

To view the video interview, please visit:
http://www.abnnewswire.net/press/en/95109/BeefLedger 

BeefLedger Ltd
WWW: www.beefledger.io
↧

Blackham Resources Ltd (ASX:BLK) Quarterly Activities Report September 2018

October 23, 2018, 9:51 pm
$
0
0
Blackham Resources Ltd (ASX:BLK) (OTCMKTS:BKHRF) ('Blackham' or 'the Company') provides the following update on its activities for the quarter ended 30 September 2018 and thereafter:

Highlights

Matilda-Wiluna Gold Operation

- Over the last three quarters gold production has been successfully stabilised at an average of 19,700oz per quarter

- Sep'18 quarterly gold production of 19,049oz (Jun'18 Qtr: 19,393oz)

- Record throughput in Sep'18 quarter of 556kt (Jun'18 Qtr: 535kt)

- Strong production in month of Sep'18 of 7,355oz and record weekly production of 2,127oz achieved in the final week of Sep'18

- All in Sustaining Costs per ounce ('AISC') for the Sep'18 quarter was A$1,588/oz (Jun'18 Qtr: $1,509/oz), in line with forecast as highlighted in our previous quarterly

- Investment in the additional mining material movements from 550KBCM per month in Jun'18 quarter, ramping up to 745kBCM in the month of Sep'18, resulted in higher overall costs this quarter which was required to match higher mill throughput

- Higher grade Wiluna ore is expected to increase production in the Dec'18 quarter

- Expecting Dec'18 quarter production of 20,000-23,000oz

- AISC/oz expected to decrease in Dec'18 quarter and over remainder of FY19

- FY19 production and cost guidance reconfirmed at 77-89koz @ an AISC of A$1,250-$1,450/oz

Reserve Development, Resources and Exploration

- Blackham delivers resources increase of 9% to 96Mt @ 2.2g/t for 6.7Moz (58% Indicated Resource)

- Golden Age underground mine plan was extended by a further 4 months to Apr'19 during the quarter, boosting high grade ore in the back half of FY19

- Additional Wiluna high grade free-milling mineralisation identified from drilling at East-West, Golden Age North and Happy Jack Pits that is likely to result in enhancements to the short-term mine plan

- Lake Way drilling confirms large mineralised gold system and further drilling planned this quarter

Corporate

- Cash and Bullion at 30 September was $8.9m (Jun'18: $23.9m)

- Net debt at 30 September was $11.0m (Jun'18: $8.4m)

- Lind Partners have agreed to invest up to A$23 million providing back up working capital

- Orion Fund JV Limited fully repaid in early Oct'18, strengthening the balance sheet

- Board strengthened further with the addition of Mr Geoff Jones as a Non-Executive Director

Non Core Assets

- A-Cap Resources Limited (ACB) agree to pay consideration of $5.8 million to Blackham and invest $5 million in the Wiluna Nickel-Cobalt Project to acquire up to 75% of the Wiluna Nickel-Cobalt Project

- Salt Lake Potash (SO4) announces a Scoping Study on development of a 50,000tpa sulphate of potash Demonstration Plant at Lake Way which supports a low capex, highly profitable operation

- SO4 gains mining approvals for initial Lake Way demonstration ponds

Blackham's Managing Director Bryan Dixon said "Our production performance in the Sep'18 quarter demonstrates further consistency in our operations. During the quarter, foundations were established for mining at our Wiluna free-milling open pits, creating the pathway to access higher grade ore at a lower cost-base moving forward."

To view the full report, please visit:
http://abnnewswire.net/lnk/I783U3W3 

Milan Jerkovic
Executive Chairman
T: +61-8-9322-6418 

Bryan Dixon 
Managing Director
T: +61-8-9322-6418

Jim Malone
Investor Relations
T: +61-419-537-714

Chantelle O'Sullivan
Media Relations
Citadel-MAGNUS
T: +61-8-6160-4900
↧
Search

FINANCE VIDEO: BeefLedger Ltd (SOAR:BEEF) Interview with Warwick Powell

October 23, 2018, 10:35 pm
$
0
0
BeefLedger Ltd (SOAR:BEEF) Director Warwick Powell is interviewed by Tim Mckinnon of ABN Newswire regarding tackling food fraud with blockchain technology.

Beefledger is driven by a belief that consumers and all supply chain participants can benefit from greater transparency and streamlined transactions in the beef supply chain.

Food safety and fraud concerns are massive issues, especially in places like China. Australia is a premium producer of safe, high quality food products - including beef - which is increasingly sought out by Chinese consumers. BeefLedger is developing and commercialising an integrated blockchain-enabled beef provenance platform and smart contracting payments regime that streamlines payments and strengthens consumer confidence in product credentialing.

To view the video interview, please visit:
http://www.abnnewswire.net/press/en/95115/BeefLedger 

BeefLedger Ltd
WWW: www.beefledger.io
↧

Argent Minerals Limited (ASX:ARD) Non-Renounceable Entitlement Offer

October 23, 2018, 10:44 pm
$
0
0
Argent Minerals Limited (ASX:ARD) (the Company) is seeking to raise up to approximately $1,739,848 (before costs) through a pro rata non-renounceable entitlements offer of one (1) fully paid ordinary share in the capital of the Company (Share) for every four (4) Shares held by eligible shareholders on 31 October 2018 at an issue price of $0.015 per Share, together with one (1) new attaching option to acquire a Share (Option) for every two (2) Shares subscribed for and issued (New Options) (Entitlement Offer). There is no minimum subscription in respect of the Entitlement Offer.

Indicative use of proceeds of Entitlement Offer

The Company intends to apply the funds raised from the Offer after expenses towards two significant drilling programmes planned for the Kempfield and Pine Ridge Gold Mine projects, each 4,200 metres and 800 metres respectively, wide area geochemical survey work for Pine Ridge, and general working capital. This is a statement of the Board's current intentions as at the date of this announcement. The Board reserves the right to alter the way the funds are applied.

Summary of the Entitlement Offer

1. The Entitlement Offer comprises one (1) new Share for every four (4) existing Shares held by existing eligible shareholders on the record date (being 31 October 2018) at $0.015 cents per Share, together with one (1) New Option for every two (2) Shares subscribed for and issued.

2. Eligible shareholders will comprise those shareholders with a registered address in Australia or New Zealand.

3. The Entitlement Offer is not underwritten.

4. Any fractional entitlements arising from the Entitlement Offer will be rounded down.

5. Shares issued under the Entitlement Offer will rank equally with existing Shares on issue on the record date. The Company will make application for official quotation of the new Shares proposed to be issued under the Entitlement Offer. Share entitlements are non-renounceable and will not be tradeable on the ASX or otherwise transferable.

6. Up to approximately 115,989,870 Shares and 57,994,935 Options will be issued pursuant to the Entitlement Offer. Shareholders who do not take up all or any part of their entitlement will not receive any payment or value in respect of the entitlement not taken up and their equity interest in the Company will be diluted.

7. The Company reserves the right to issue Shares and New Options comprising the shortfall within three months after the closing date of the Entitlement Offer on the same terms as the Entitlement Offer (Shortfall Offer).

8. The Company is also seeking shareholder approval for the right to issue Shares and New Options under the Shortfall Offer to Directors of the Company (up to an amount of $133,000) at its upcoming annual general meeting to be held on 28 November 2018. The Shares and New Options to be issued to the Directors under the Shortfall Offer (if any) will be issued within one month of the date of obtaining shareholder approval.

Timetable

Further details of the Entitlement Offer, including details on how to accept and key risks of the Entitlement Offer will be set out in a prospectus which is expected to be released to the ASX on 25 October 2018 and dispatched to shareholders on 5 November 2018. Outlined below is a timetable of relevant events and dates relating to the Entitlement Offer. These events and dates are indicative only and subject to change. Subject to the ASX Listing Rules, the Corporations Act and other applicable laws, the Company's Board reserves the right to modify all dates, including the Entitlement Offer closing date.

Announce Rights Issue: 24 October 2018

Lodgement of Prospectus with the ASIC: 25 October 2018

Lodgement of Prospectus & Appendix 3B with ASX : 25 October 2018

Notice sent to Option holders: 29 October 2018

Notice sent to Shareholders: 29 October 2018

Ex date: 30 October 2018

Record Date for determining Entitlements: 31 October 2018

Prospectus sent out to Shareholders & Company announces this has been completed: 5 November 2018

Closing Date*: 13 November 2018

Shares quoted on a deferred settlement basis: 14 November 2018

ASX notified of under subscriptions: 16 November 2018

Issue date/Securities entered into Shareholders' security holdings: 20 November 2018

Quotation of Securities issued under the Offer*: 21 November 2018

Application for new Shares and New Options under the Entitlement Offer may only be made by completing the Application Form which accompanies the prospectus. Shareholders eligible to participate in the Entitlement Offer should read the prospectus carefully and consult professional advisers as necessary. 

Enquiries
Any enquiries regarding the Entitlement Offer should be directed to: 

Vinod Manikandan
Company Secretary
Phone: +61-2-9300-3390
↧
↧

Cervantes Corporation Limited (ASX:CVS) Capital Raising

October 24, 2018, 3:30 pm
$
0
0
Cervantes Corporation Ltd (ASX:CVS) (Cervantes, the Company) is pleased to announce a capital raising of $700,000 by way of a Prospectus as released today.

The capital raising will be primarily for the purpose of providing additional funds for the imminent drilling of Cervantes 2 gold project areas in the Meekatharra and Payne's Find districts.

The Albury Heath project in Meekatharra which delivered exceptional drill results of 2m @ 67.2 g/t ( 2oz) from 27m in AHP116, incl 1m @ 129.3 g/t ( 4oz) from 27m and 5m @ 63.1 g/t (2oz) from 32m in AHP134, incl 1m @ 202.8 g/t ( 6.5oz) from 33m (as released on the 28th June 2018) is about to commence a further follow up drilling program immediately upon finalisation of the drilling tender process currently underway.

The Primrose project in Payne's Find will also receive a follow up drilling program based on the extremely successful air core drilling program, and the RAB drilling program in 2017 which produced elevated gold and Nickel/Cobalt/Copper results as released on the 12th June 2018.

The Paynes Find goldfield was described by a Government Geologist in 1920 as being of similar Geology to the Edna May gold mine in Westonia (sourced: Mindat website "Paynes Find Goldfield, Goodingnow") and the geological setting of the RAB results at Paynes for Nickel/Cobalt was stated by Cervantes exploration Manager as being analogous to the Emily May nickel deposit, west of Norseman (Peters and Buck, 2000, The Maggie Hays and Emily Ann nickel deposits, Western Australia: A geophysical case history, Expl Geophys, 31, 210-221). We expect this program to follow on from the Albury Heath drilling program.

The company is very excited about the exploration potential of these quality projects in a rising Gold price market with the dual targets of two of the most sought after Metals.

To view the Prospectus, please visit:
http://abnnewswire.net/lnk/J47N8GP0 

Collin Vost
Chairman
T: +61-8-6436-2300
E: admin@cervantescorp.com.au
↧

Collaborate Corporation Ltd (ASX:CL8) Shortfall on Underwritten Entitlement Issue

October 24, 2018, 3:31 pm
$
0
0
Collaborate Corporation Limited (ASX:CL8) (Collaborate or the Company) advises that the partially underwritten 1 for 8 non-renounceable entitlement offer of fully paid ordinary shares (Shares) to existing eligible shareholders (Entitlement Issue) closed on 22 October 2018.

Collaborate received a strong response from its shareholders, particularly in relation to application for Shortfall Shares, with 69,284,711 Shares subscribed for representing a take up of 90% of the total Shares offered under the Entitlement Issue and raising $1.04 million.

The Company advises the results of the Entitlement Issue as follows: 

------------------------------------------------------------------
                      Number of Shares    $            Number of 
                                                      shareholders
------------------------------------------------------------------
Number of Shares                                      
available under the
Entitlement Issue       77,389,732       $1,160,846     1,670 
------------------------------------------------------------------
Number of Shares 
subscribed for under 
the Entitlement Issue   69,284,711       $1,039,271      294
------------------------------------------------------------------
Number of Shortfall 
Shares                  8,105,021        $121,575        N/A 
------------------------------------------------------------------

The results of the Entitlement Issue include advances made by the underwriters, sophisticated investors Hishenk Pty Ltd, Reefpeak Pty Ltd, Mishki Pty Ltd, Scintilla Strategic Investments Limited, alongside officers of the Company: Chris Noone, Adrian Bunter and Karen Logan.

Pursuant to the Entitlement Issue Prospectus dated 14 September 2018 and Underwriting Agreements, all acceptances of entitlements and applications for shortfall under the Entitlement Issue will be allotted in full and the Underwriters have been notified of the shortfall.

CEO and Executive Director, Mr Chris Noone, said "We take this opportunity to thank Collaborate's shareholders, both large and small, for their support and participation."

The Company will proceed to allot and issue the Shares in accordance with the Entitlement Issue timetable. 

Collaborate Corporation Limited
Tel: +61-2-8889-3641
E: shareholder@collaboratecorp.com 
W: www.collaboratecorp.com
↧

Cobalt Blue Holdings Limited (ASX:COB) Thackaringa Joint Venture Update

October 24, 2018, 3:44 pm
$
0
0
Cobalt Blue Holdings Limited (ASX:COB) (OTCMKTS:CBBHF) announces the Company decides not to exercise its rights to proceed further under Thackaringa Joint Venture Farmin Earning Period provisions.

KEY POINTS:

- Following completion of a Pre-Feasibility Study (PFS), the Thackaringa Joint Venture commissioned Wood PLC, a globally renowned engineering firm, to perform a PFS gap analysis review. Wood subsequently recommended up to a 24 month period for further Bankable Feasibility Study (BFS) work.

- COB has concluded that the risk of attempting to fast track such studies into a period of only 12 months, to meet the BFS timetable in the Exploration Farmin Joint Venture Agreement (Farmin Agreement) with Broken Hill Prospecting Limited (ASX:BPL), would significantly impair the project and pose undesirable risk. Subsequently, after a period of negotiations leading to no acceptable commercial outcomes, COB has now elected out of the Earning Period process of the Farmin Agreement.

- Notwithstanding COB's decision, it will continue to hold its recently upgraded and announced 70% beneficial interest in the project.

- COB will remain in the Thackaringa Cobalt Project as a Joint Venture partner with BPL (30% beneficial interest). COB will now work with our JV partner, BPL to progress the Thackaringa Cobalt Project through development and feasibility studies, and assuming positive results, and into the construction and ultimately production phases.

- COB will remain Manager of the Joint Venture.

Previously we have updated the market on the Wood Review and its bearing on feasibility studies. The review clearly outlined that it is prudent, particularly where complex operations are concerned, for there to be an extended development and testwork phase prior to moving onto the next stage of studies. Wood concluded that the pre-BFS work, completion of flowsheet development, additional bulk scale testwork, demonstration operations and feasibility studies will take up to 24 months.

As COB is committed to using an industry best practice approach to deliver the world class Thackaringa Cobalt Project, it will implement the recommendations of the Wood review to improve the technical robustness of the pre-planning, preparation and technical work required to support the full cobalt sulphate flowsheet. COB continues to believe that Thackaringa's future lies in making a battery ready ingredient that captures the entire cobalt margin through cycle for our shareholders.

COB is currently finalising the timeline for such feasibility studies, with a view to preserving the board investment decision date to Q3 2020. The ability to deliver a higher quality, more rigorous feasibility study in the interim, one that de-risks the project, is our primary focus.

Due to these reasons we are unable to deliver a BFS by mid 2019, which is required under the Earning Period provisions of the Farmin Agreement. The COB board believes that to attempt to rush these studies, without proper diligence, is imprudent and not in the best interests of the Thackaringa Cobalt Project or COB's shareholders. As a result, COB is unable to progress further within the Earning Period provisions in the Farmin Agreement and has elected to stay within the Joint Venture as a 70% partner. We therefore welcome BPL as our 30% JV equity partner and look forward to developing the project with its assistance.

Cobalt Blue has the following beneficial interests in the tenements:

- EL 6622 - 70% beneficial interest.

- EL 8143 - 70% beneficial interest.

- ML 86 - 70% beneficial interest.

- ML 87 - 70% beneficial interest. 

Joe Kaderavek
Chief Executive Officer
Cobalt Blue Holdings Limited
Ph: +61-2-8287-0660
Website: www.cobaltblueholdings.com
Email: info@cobaltblueholdings.com
↧
Viewing all 12704 articles
Browse latest View live
More Pages to Explore .....
Search

Latest Images

Ukraine bans military from online gambling amid addiction concerns

Ukraine bans military from online gambling amid addiction concerns

April 22, 2024, 5:17 am
ಮಂಡ್ಯದಿಂದ ಸುಮಲತಾ ದೂರ; ಹೆಚ್‌ಡಿಕೆ ಪರ ಪ್ರಚಾರಕ್ಕಿಳಿಯದ ಸಂಸದೆ –ಬರ್ತಾರೆ ನೋಡೋಣ ಎಂದ...

ಮಂಡ್ಯದಿಂದ ಸುಮಲತಾ ದೂರ; ಹೆಚ್‌ಡಿಕೆ ಪರ ಪ್ರಚಾರಕ್ಕಿಳಿಯದ ಸಂಸದೆ –ಬರ್ತಾರೆ ನೋಡೋಣ ಎಂದ...

April 20, 2024, 8:08 pm
OCBC Bank Singapore Offers Up to 2.8% p.a. Fixed Deposit Promotion from 21...

OCBC Bank Singapore Offers Up to 2.8% p.a. Fixed Deposit Promotion from 21...

April 20, 2024, 12:38 pm
National Poetry Month 2024: Maxine Starr

National Poetry Month 2024: Maxine Starr

April 19, 2024, 9:56 am
Vegan Chicken Pot Pie

Vegan Chicken Pot Pie

April 19, 2024, 9:18 am
Firefox UX: On Purpose: Collectively Defining Our Team’s Mission Statement

Firefox UX: On Purpose: Collectively Defining Our Team’s Mission Statement

April 19, 2024, 7:03 am
New $4.5 million East Bay trail path will connect bicyclists, pedestrians to...

New $4.5 million East Bay trail path will connect bicyclists, pedestrians to...

April 18, 2024, 11:05 am
Photographer Gifts for Clients / Print Packaging / 4x6 Photo Box by...

Photographer Gifts for Clients / Print Packaging / 4x6 Photo Box by...

April 17, 2024, 6:48 pm
Deepfake Video of Aamir Khan circulates Online

Deepfake Video of Aamir Khan circulates Online

April 17, 2024, 3:07 am
Very Hungry Caterpillar™ Shirt: World of Eric Carle™+ Little Goodall by...

Very Hungry Caterpillar™ Shirt: World of Eric Carle™+ Little Goodall by...

April 14, 2024, 8:14 am